Chios mastic treatment of patients with active Crohn's disease

World Journal of Gastroenterology

Volumn 13, Issue 5, 2007, Pages 748-753

  Kaliora, Andriana C ^a   Stathopoulou, Maria G ^a   Triantafillidis, John K ^b   Dedoussis, George V Z ^a   Andrikopoulous, Nikolaos K ^a  

^a HAROKOPIO UNIVERSITY   (Greece)

^b Saint Panteleimon General Hospital   (Greece)

Author keywords

Antioxidant potential; C reactive protein; Chios mastic; Conservative treatment; Crohn's disease; Cytokines

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INTERLEUKIN 6; MESALAZINE; METRONIDAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; PISTACIA LENTISCUS EXTRACT; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; OUTPATIENT DEPARTMENT; PILOT STUDY; STATISTICAL SIGNIFICANCE;

EID: 33846984273     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i5.748     Document Type: Article

References (37)

1. Triantafillidis JK, Emmanouilidis A, Manousos O, Nicolakis D, Kogevinas M. Clinical patterns of Crohn's disease in Greece: a follow-up study of 155 cases. Digestion 2000; 61: 121-128
2. Triantafillidis JK, Emmanouilidis A, Nicolakis D, Ifantis T, Cheracakis P, Merikas EG. Crohn's disease in the elderly: clinical features and long-term outcome of 19 Greek patients. Dig Liver Dis 2000; 32: 498-503
3. Triantafillidis JK, Emmanouilidis A, Nicolakis D, Cheracakis P, Kogevinas M, Merikas E, Hereti I, Argyros N. Surgery for Crohn's disease in Greece: a follow-up study of 79 cases. Hepatogastroenterology 2001; 48: 1072-1077
4. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10
5. Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol 2001; 13: 777-784
6. Grip O, Janciauskiene S, Lindgren S. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflamm Bowel Dis 2004; 10: 193-200
7. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344: 859-861
8. Trebble TM, Stroud MA, Wootton SA, Calder PC, Fine DR, Mullee MA, Moniz C, Arden NK. High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial. Br J Nutr 2005; 94: 253-261
9. Lavy A, Naveh Y, Coleman R, Mokady S, Werman MJ. Dietary Dunaliella bardawil, a beta-carotene-rich alga, protects against acetic acid-induced small bowel inflammation in rats. Inflamm Bowel Dis 2003; 9: 372-379
10. Kwon KH, Murakami A, Tanaka T, Ohigashi H. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. Biochem Pharmacol 2005; 69: 395-406
11. Levi AJ. Diet in the management of Crohn's disease. Gut 1985; 26: 985-988
12. Dedoussis GV, Kaliora AC, Psarras S, Chiou A, Mylona A, Papadopoulos NG, Andrikopoulos NK. Antiatherogenic effect of Pistacia lentiscus via GSH restoration and downregulation of CD36 mRNA expression. Atherosclerosis 2004; 174: 293-303
13. Huwez FU, Thirlwell D, Cockayne A, Ala'Aldeen DA. Mastic gum kills Helicobacter pylori. N Engl J Med 1998; 339: 1946
14. Al-Said MS, Ageel AM, Parmar NS, Tariq M. Evaluation of mastic, a crude drug obtained from Pistacia lentiscus for gastric and duodenal anti-ulcer activity. J Ethnopharmacol 1986; 15: 271-287
15. Loughlin MF, Ala'Aldeen DA, Jenks PJ. Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice. J Antimicrob Chemother 2003; 51: 367-371
16. Bebb JR, Bailey-Flitter N, Ala'Aldeen D, Atherton JC. Mastic gum has no effect on Helicobacter pylori load in vivo. J Antimicrob Chemother 2003; 52: 522-523
17. Janakat S, Al-Merie H. Evaluation of hepatoprotective effect of Pistacia lentiscus, Phillyrea latifolia and Nicotiana glauca. J Ethnopharmacol 2002; 83: 135-138
18. Ljubuncic P, Song H, Cogan U, Azaizeh H, Bomzon A. The effects of aqueous extracts prepared from the leaves of Pistacia lentiscus in experimental liver disease. J Ethnopharmacol 2005; 100: 198-204
19. Liu J. Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 2005; 100: 92-94
20. Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol 2003; 94: 449-455
21. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-869
22. Chan AT, Fleming CR, O'Fallon WM, Huizenga KA. Estimated versus measured basal energy requirements in patients with Crohn's disease. Gastroenterology 1986; 91: 75-78
23. Duerksen DR, Nehra V, Bistrian BR, Blackburn GL. Appropriate nutritional support in acute and complicated Crohn's disease. Nutrition 1998; 14: 462-465
24. Arai F, Takahashi T, Furukawa K, Matsushima K, Asakura H. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease. Dig Dis Sci 1998; 43: 2071-2079
25. Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514-519
26. Assimopoulou AN, Papageorgiou VP. GC-MS analysis of penta- and tetra-cyclic triterpenes from resins of Pistacia species. Part I. Pistacia lentiscus var. Chia. Biomed Chromatogr 2005; 19: 285-311
27. Andrikopoulos NK, Kaliora AC, Assimopoulou AN, Papapeorgiou VP. Biological activity of some naturally occurring resins, gums and pigments against in vitro LDL oxidation. Phytother Res 2003; 17: 501-507
28. Kaliora AC, Mylona A, Chiou A, Petsios DG, Andrikopoulos NK. Detection and identification of simple phenolics in Pistacia lentiscus resin. J Liq Chrom Rel Technol 2004; 27: 289-300
29. Maeda M, Watanabe N, Neda H, Yamauchi N, Okamoto T, Sasaki H, Tsuji Y, Akiyama S, Tsuji N, Niitsu Y. Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 1992; 14: 451-461
30. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, Fiocchi C. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993; 104: 749-758
31. Ping D, Boekhoudt GH, Rogers EM, Boss JM. Nuclear factor-kappa B p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. J Immunol 1999; 162: 727-734
32. Cho IJ, Lee AK, Lee SJ, Lee MG, Kim SG. Repression by oxidative stress of iNOS and cytokine gene induction in macrophages results from AP-1 and NF-kappaB inhibition mediated by B cell translocation gene-1 activation. Free Radic Biol Med 2005; 39: 1523-1536
33. Cao G, Booth SL, Sadowski JA, Prior RL. Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. Am J Clin Nutr 1998; 68: 1081-1087
34. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005; 81: 230S-242S
35. Halliwell B, Zhao K, Whiteman M. The gastrointestinal tract: a major site of antioxidant action? Free Radic Res 2000; 33: 819-830
36. Yano S, Harada M, Watanabe K, Nakamaru K, Hatakeyama Y, Shibata S, Takahashi K, Mori T, Hirabayashi K, Takeda M. Antiulcer activities of glycyrrhetinic acid derivatives in experimental gastric lesion models. Chem Pharm Bull (Tokyo) 1989; 37: 2500-2504
37. Hou YC, Ching H, Chao PD, Tsai SY, Wen KC, Hsieh PH, Hsiu SL. Effects of glucose, fructose and 5-hydroxymethyl-2-furaldehyde on the presystemic metabolism and absorption of glycyrrhizin in rabbits. J Pharm Pharmacol 2005; 57: 247-251